Changes in lung function and chylous effusions in patients with lymphangioleiomyomatosis treated with sirolimus.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Annals of Internal Medicine

• Publication date

  2011-06-21

• Fields of study

  Medicine

• Identifiers
  DOI 10.7326/0003-4819-154-12-201106210-00007PMID 21690594PMCID PMC3176735
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Efficacy and safety of sirolimus in lymphangioleiomyomatosis.

  2011cited by this paper
• Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis.

  2010cited by this paper
• Angiomyolipomata: challenges, solutions, and future prospects based on over 100 cases treated

  2010cited by this paper
• PI3K/mTORC1 activation in hamartoma syndromes: Therapeutic prospects

  2009cited by this paper
• Involvement of Lymphatics in Lymphangioleiomyomatosis

  2009cited by this paper
• Sirolimus therapy in tuberous sclerosis or sporadic lymphangioleiomyomatosis.

  2008cited by this paper
• Sirolimus ameliorated post lung transplant chylothorax in lymphangioleiomyomatosis.

  2008cited by this paper
• Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis.

  2008cited by this paper
• Sirolimus amelioration of clinical symptoms of recurrent lymphangioleiomyomatosis after living-donor lobar lung transplantation.

  2008cited by this paper
• Pulmonary lymphangioleiomyomatosis (LAM): Progress and current challenges

  2008cited by this paper
• Lymphangioleiomyomatosis: a clinical update.

  2008cited by this paper
• The epidemiology of lymphangioleiomyomatosis in Japan: A nationwide cross‐sectional study of presenting features and prognostic factors

  2007cited by this paper
• Sirolimus treatment for pulmonary lymphangioleiomyomatosis.

  2007cited by this paper
• The NHLBI lymphangioleiomyomatosis registry: characteristics of 230 patients at enrollment.

  2006cited by this paper
• Pleural disease in lymphangioleiomyomatosis.

  2006cited by this paper
• Emerging clinical picture of lymphangioleiomyomatosis

  2005cited by this paper
• SERIES ''ATS/ERS TASK FORCE: STANDARDISATION OF LUNG FUNCTION TESTING'' Edited by V. Brusasco, R. Crapo and G. Viegi Number 4 in this Series Standardisation of the single-breath determination of carbon monoxide uptake in the lung

  2005cited by this paper
• Efficacy of a rapamycin analog (CCI-779) and IFN-gamma in tuberous sclerosis mouse models.

  2005cited by this paper
• Standardisation of spirometry

  2005cited by this paper
• Effects of Rapamycin in the Eker Rat Model of Tuberous Sclerosis Complex

  2005cited by this paper
• Efficacy of a rapamycin analog (CCI‐779) and IFN‐γ in tuberous sclerosis mouse models

  2005cited by this paper
• Decline in lung function in patients with lymphangioleiomyomatosis treated with or without progesterone.

  2004cited by this paper
• Renal angiomyolipomata.

  2004cited by this paper
• Successful octreotide treatment of chylous pleural effusion and lymphedema in the yellow nail syndrome.

  2004cited by this paper
• Survival and disease progression in UK patients with lymphangioleiomyomatosis

  2004cited by this paper
• Perturbed IFN-gamma-Jak-signal transducers and activators of transcription signaling in tuberous sclerosis mouse models: synergistic effects of rapamycin-IFN-gamma treatment.

  2004cited by this paper
• Perturbed IFN-γ-Jak-Signal Transducers and Activators of Transcription Signaling in Tuberous Sclerosis Mouse Models

  2004cited by this paper
• Low initial KCO predicts rapid FEV1 decline in pulmonary lymphangioleiomyomatosis.

  2004cited by this paper
• Use of LeVeen pleuroperitoneal shunt for refractory high-volume chylothorax.

  2004cited by this paper
• The hidden cost of medical liability litigation

  2004cited by this paper
• Tuberous sclerosis complex gene products, Tuberin and Hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb.

  2003cited by this paper
• Atypical presentation of lymphangioleiomyomatosis as acute abdomen: CT diagnosis.

  2003cited by this paper
• Chylothorax in lymphangioleiomyomatosis.

  2003cited by this paper
• Localized retroperitoneal lymphangioleiomyomatosis mimicking malignancy. A case report and review of the literature.

  2003cited by this paper
• Lymphangioleiomyomatosis initially presenting with abdominal pain: a case report.

  2003cited by this paper
• Octreotide in the treatment of chylothorax.

  2002cited by this paper
• Tuberin Regulates p70 S6 Kinase Activation and Ribosomal Protein S6 Phosphorylation

  2002cited by this paper
• Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling

  2002cited by this paper
• Prevalence and clinical characteristics of lymphangioleiomyomatosis (LAM) in patients with tuberous sclerosis complex.

  2001cited by this paper
• Mutational and radiographic analysis of pulmonary disease consistent with lymphangioleiomyomatosis and micronodular pneumocyte hyperplasia in women with tuberous sclerosis.

  2001cited by this paper
• High frequency of pulmonary lymphangioleiomyomatosis in women with tuberous sclerosis complex.

  2000cited by this paper
• Lymphangioleiomyomatosis: abdominopelvic CT and US findings.

  2000cited by this paper
• Mutations in the tuberous sclerosis complex gene TSC2 are a cause of sporadic pulmonary lymphangioleiomyomatosis.

  2000cited by this paper
• The TSC1 tumour suppressor hamartin regulates cell adhesion through ERM proteins and the GTPase Rho

  2000cited by this paper
• Extrapulmonary lymphangioleiomyomatosis (LAM): clinicopathologic features in 22 cases.

  2000cited by this paper
• Evidence that lymphangiomyomatosis is caused by TSC2 mutations: chromosome 16p13 loss of heterozygosity in angiomyolipomas and lymph nodes from women with lymphangiomyomatosis.

  1998cited by this paper
• Identification and characterization of the tuberous sclerosis gene on chromosome 16

  1993cited by this paper
• Epidemiology of Tuberous Sclerosis

  1991cited by this paper

• Determinants of adherence to sirolimus among lymphangioleiomyomatosis patients.

  2026cites this paper
• Novel treatment strategies for lymphangioleiomyomatosis: a narrative review

  2025cites this paper
• Brazilian Thoracic Association recommendations for the management of lymphangioleiomyomatosis

  2025cites this paper
• Current Perspectives on The Diagnosis and Management of Lymphangioleiomyomatosis.

  2025cites this paper
• Illness cognition, illness perception and related factors in patients with lymphangioleiomyomatosis

  2025cites this paper
• Current concepts in the pathogenesis and clinical management of lymphangioleiomyomatosis.

  2025cites this paper
• Influence of preoperative nutritional status on postoperative dysphagia in lung transplantation.

  2025cites this paper
• Emerging Concepts in Pathogenesis, Multiomics Applications, and Clinical Research in Lymphangioleiomyomatosis

  2025cites this paper
• Seltene Lungenerkrankungen: Die Therapie macht Fortschritte

  2025cites this paper
• Iron metabolism disorder and artesunate inhibiting tumor growth by inducing ferroptosis in Lymphangioleiomyomatosis

  2025cites this paper
• mTOR pathway diseases: challenges and opportunities from bench to bedside and the mTOR node

  2025cites this paper
• Evolution of DLCO in LAM: Historical Perspectives and the Role of Advanced Imaging.

  2024cites this paper
• Chylothorax de l’adulte

  2024cites this paper
• PEComas: A review of imaging and clinical features.

  2024cites this paper
• Surgical Management of Pleural Complications in Lymphangioleiomyomatosis.

  2024cites this paper
• A chylothorax in a young woman: The difficulties of medical management

  2024cites this paper
• Diagnosis of cystic lung diseases: a position statement from the UK Cystic Lung Disease Rare Disease Collaborative Network

  2024cites this paper
• Tissue‐Engineered Disease Modeling of Lymphangioleiomyomatosis Exposes a Therapeutic Vulnerability to HDAC Inhibition

  2023cites this paper
• French recommendations for the diagnosis and management of lymphangioleiomyomatosis.

  2023cites this paper
• Upregulation of acid ceramidase contributes to tumor progression in tuberous sclerosis complex

  2023cites this paper
• Lymphangioleiomyomatosis.

  2023cites this paper
• Lymphangioleiomyomatosis and mTOR inhibitors in real world—a narrative review

  2023cites this paper
• Effects of Sirolimus on Anti-SARS-CoV2 Vaccination in Patients with LAM.

  2023cites this paper
• Lymphangioleiomyomatosis and Other Cystic Lung Diseases.

  2023cites this paper
• Lymphangioleiomyomatose

  2022cites this paper
• A Mixed Blood-Lymphatic Endothelial Cell Phenotype in Lymphangioleiomyomatosis and Idiopathic Pulmonary Fibrosis but Not in Kaposi ’ s Sarcoma or Tuberous Sclerosis Complex

  2022cites this paper
• Lung transplantation for lymphangioleiomyomatosis.

  2022cites this paper
• Long-term clinical course and outcomes in patients with lymphangioleiomyomatosis

  2022cites this paper
• Computer grading of lung disease severity in patients with lymphangioleiomyomatosis referred for transplantation

  2022cites this paper
• Dysregulation of Acid Ceramidase-mediated Sphingolipid Metabolism Contributes to Tumor Progression in Tuberous Sclerosis Complex

  2022cites this paper
• Prospective nanoparticle treatments for lymphangioleiomyomatosis

  2022cites this paper
• A Mixed Blood-Lymphatic Endothelial Cell Phenotype in LAM and IPF but not in Kaposi's Sarcoma or TSC.

  2022cites this paper
• Perfect match: mTOR inhibitors and tuberous sclerosis complex

  2022cites this paper
• Imaging Findings of Thoracic Lymphatic Abnormalities.

  2022cites this paper
• Long-term clinical course and progression of lymphangioleiomyomatosis in a single lung transplant referral centre in Korea

  2022cites this paper
• Lymphangioleiomyomatosis: pathogenesis, clinical features, diagnosis, and management.

  2021cites this paper
• Methacholine reactivity in lymphangioleiomyomatosis is inversely related to FEV1 and VEGF-D

  2021cites this paper
• Long-term effects of sirolimus on human skin TSC2-null fibroblast-like cells.

  2021cites this paper
• Sclerosi tuberosa ed everolimus: una nuova storia

  2021cites this paper
• Diagnosis and treatment of lymphangioleiomyomatosis (LAM) from the PEComa group

  2021influential citation
• Improving Survival in Lymphangioleiomyomatosis: A 16-Year Observational Study in a Large Cohort of Patients

  2021cites this paper
• Reduced risk of recurrent pneumothorax for sirolimus therapy after surgical pleural covering of entire lung in lymphangioleiomyomatosis

  2021cites this paper
• Pleural Disease in Diffuse Cystic Lung Diseases

  2021cites this paper
• Extrapulmonary Manifestations of Diffuse Cystic Lung Diseases

  2021cites this paper
• Mechanisms of Lung Cyst Formation

  2021cites this paper
• Chylothorax and Pseudochylothorax.

  2021cites this paper
• Rapid Shrinkage of Retroperitoneal Lymphangioleiomyoma after Sirolimus Initiation

  2021cites this paper
• A breathless teenager

  2021cites this paper
• Tuberous sclerosis complex for the pulmonologist

  2021cites this paper
• Lung Diseases Unique to Women.

  2021cites this paper
• Recycling plastic: diagnosis and management of plastic bronchitis among adults

  2021cites this paper
• Three-dimensional drug screen identifies HDAC inhibitors as therapeutic agents in mTORC1-driven lymphangioleiomyomatosis

  2021cites this paper
• Diffuse cystic lung disease

  2020cites this paper
• Refractory chylous effusions in lymphangioleiomyomatosis patient post lung transplant

  2020cites this paper
• Zoledronic acid inhibits TSC2-null cell tumor growth via RhoA/YAP signaling pathway in mouse models of lymphangioleiomyomatosis

  2020cites this paper
• The efficacy and safety of pharmacological treatments for lymphangioleiomyomatosis

  2020cites this paper
• Quantitative analysis of computed tomography of the lungs in patients with lymphangioleiomyomatosis treated with sirolimus

  2020cites this paper
• Lymphangioleiomyomatosis

  2020cites this paper
• Possible Novel Therapeutic Targets in Lymphangioleiomyomatosis Treatment

  2020cites this paper
• Ultra-rare cystic disease

  2020cites this paper
• PEComas: An Uncommon Family of Sarcomas Sensitive to Targeted Therapy

  2020cites this paper
• Long-term efficacy and safety of sirolimus therapy in patients with lymphangioleiomyomatosis

  2019cites this paper
• mTOR inhibitors for the management of difficult lymphangioma in adults.

  2019cites this paper
• Effects of Sirolimus on Lung function in patients with Lymphangioleiomyomatosis

  2019cites this paper
• Angiotensin-converting enzyme inhibitors may affect pulmonary function in lymphangioleiomyomatosis.

  2019cites this paper
• The National Heart, Lung, and Blood Institute Lymphangioleiomyomatosis Registry: Making LAMonade out of LAMons.

  2019cites this paper
• Highly effective sirolimus therapy for abdominal lymphangioleiomyoma.

  2019cites this paper
• Lymphangioléiomyomatose pulmonaire

  2019cites this paper
• Use of CT Imaging to Quantify Progression and Response to Treatment in Lymphangioleiomyomatosis

  2019cites this paper
• Sirolimus in lymphangioleiomyomatosis: A case in point for research in ‘orphan’ diseases

  2019cites this paper
• Early postoperative complications after lung transplantation

  2019cites this paper
• Low-dose sirolimus in retroperitoneal lymphangioleiomyomas

  2019cites this paper
• The Lymphangioleiomyomatosis Lung Cell and Its Human Cell Models

  2018cites this paper
• Management of the “Other” retroperitoneal sarcomas

  2018cites this paper
• Long‐Term Effect of Sirolimus on Serum Vascular Endothelial Growth Factor D Levels in Patients With Lymphangioleiomyomatosis

  2018cites this paper
• Successful treatment of a patient with chyluria due to lymphangioleiomyomatosis using sirolimus

  2018cites this paper
• Effect of beta-agonists on LAM progression and treatment

  2018cites this paper
• Single lung transplantation for lymphangioleiomyomatosis: a single-center experience in Japan

  2018cites this paper
• Advances in understanding of lymphangioleiomyomatosis : current and emerging treatment options

  2018cites this paper
• Functional improvements in patients with lymphangioleiomyomatosis after sirolimus: an observational study

  2018cites this paper
• The 10,000-Piece Puzzle of Lymphangioleiomyomatosis.

  2018cites this paper
• Rapamycin for lymphangioleiomyomatosis: optimal timing and optimal dosage

  2018cites this paper
• Recent advances in the management of lymphangioleiomyomatosis

  2018cites this paper
• Pulmonary manifestations in tuberous sclerosis complex

  2018cites this paper
• Successful Sirolimus Treatment of Lymphangioleiomyomatosis in a Hepatitis B Virus Carrier

  2018cites this paper
• Efficacy and safety of low-dose Sirolimus in Lymphangioleiomyomatosis

  2018cites this paper
• Interstitielle Lungenerkrankungen: epidemiologische Herausforderungen, Register und Biobanken

  2018cites this paper
• Additional Octreotide Therapy to Sirolimus Achieved a Decrease in Sirolimus-refractory Chylous Effusion Complicated with Lymphangioleiomyomatosis

  2017cites this paper
• Medical Management of Pulmonary Hypertension with Unclear and/or Multifactorial Mechanisms (Group 5): Is There a Role for Pulmonary Arterial Hypertension Medications?

  2017cites this paper
• A Case of Successful Therapy by Intrapleural Injection of Fibrin Glue for Chylothorax after Lung Transplantation for Lymphangioleiomyomatosis.

  2017cites this paper
• Sirolimus for the treatment of lymphangioleiomyomatosis

  2017cites this paper
• Addressing the challenges of lymphangioleiomyomatosis assessment in the clinic

  2017cites this paper
• Chylothorax: A Review of Management Options

  2017cites this paper
• Transudative chylothorax in a patient with lymphangioleiomyomatosis

  2017cites this paper
• Protein-losing Enteropathy Caused by Intestinal or Colonic Lymphangiectasia Complicated by Sporadic Lymphangioleiomyomatosis: A Report of Two Cases

  2017cites this paper
• Rapamycin reversal of VEGF-C-driven lymphatic anomalies in the respiratory tract.

  2017cites this paper
• CA‐125 in Disease Progression and Treatment of Lymphangioleiomyomatosis

  2017cites this paper
• Recent Advances and Challenges of mTOR Inhibitors Use in the Treatment of Patients with Tuberous Sclerosis Complex

  2017cites this paper
• Treatment of Lymphangioleiomyomatosis (LAM)

  2017cites this paper
• Pelvic lymphangioleiomyomatosis treated successfully with everolimus

  2017cites this paper